Cargando…

The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma

Multiple myeloma (MM) is well-known for the development of drug resistance, leading to relapse. Therefore, finding novel treatment strategies remains necessary. By performing a lipidomics assay on MM patient plasma, we aimed to identify new targets. We observed a dysregulation in the sphingolipid me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Faict, Sylvia, Oudaert, Inge, D’Auria, Ludovic, Dehairs, Jonas, Maes, Ken, Vlummens, Philip, De Veirman, Kim, De Bruyne, Elke, Fostier, Karel, Vande Broek, Isabelle, Schots, Rik, Vanderkerken, Karin, Swinnen, Johannes V., Menu, Eline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966559/ https://www.ncbi.nlm.nih.gov/pubmed/31756922 http://dx.doi.org/10.3390/cancers11121823

Ejemplares similares

Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis
por: Oudaert, Inge, et al.
Publicado: (2022)

Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma
por: Wang, Jinheng, et al.
Publicado: (2016)

Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma
por: Oudaert, Inge, et al.
Publicado: (2022)

Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts
por: Faict, Sylvia, et al.
Publicado: (2018)

The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma
por: Vlummens, Philip, et al.
Publicado: (2019)

The genetic landscape of 5T models for multiple myeloma
por: Maes, Ken, et al.
Publicado: (2018)

AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma
por: Yan, Siyang, et al.
Publicado: (2019)

Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma
por: Maes, Anke, et al.
Publicado: (2019)

PB1973: INHIBITION OF LACTATE EXPORTERS INDUCES DIRECT ANTI-TUMOR EFFECTS AND COUNTERS IMMUNE SUPPRESSION IN MULTIPLE MYELOMA
por: Van der Vreken, A., et al.
Publicado: (2022)

The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma
por: Maes, Anke, et al.
Publicado: (2019)

The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response
por: De Smedt, Eva, et al.
Publicado: (2018)

P860: THE DE NOVO DNA METHYLTRANSFERASE DNMT3B PLAYS AN IMPORTANT ROLE IN MM CELL GROWTH, CLONOGENICITY AND DRUG RESPONSE
por: Muylaert, C., et al.
Publicado: (2022)

Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach
por: Vlummens, Philip, et al.
Publicado: (2022)

Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
por: Muylaert, Catharina, et al.
Publicado: (2022)

Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells
por: Lub, Susanne, et al.
Publicado: (2015)

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic
por: Bieghs, Liesbeth, et al.
Publicado: (2014)

Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects
por: De Beck, Lien, et al.
Publicado: (2018)

The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers
por: Fan, Rong, et al.
Publicado: (2022)

The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells
por: Wang, Jinheng, et al.
Publicado: (2015)

Metabolic Features of Multiple Myeloma
por: El Arfani, Chaima, et al.
Publicado: (2018)

Preclinical Evaluation of Invariant Natural Killer T Cells in the 5T33 Multiple Myeloma Model
por: Nur, Haneen, et al.
Publicado: (2013)

The therapeutic potential of cell cycle targeting in multiple myeloma
por: Maes, Anke, et al.
Publicado: (2017)

Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions
por: Verheye, Emma, et al.
Publicado: (2022)

Novel strategies to target the ubiquitin proteasome system in multiple myeloma
por: Lub, Susanne, et al.
Publicado: (2015)

Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma
por: Fan, Rong, et al.
Publicado: (2023)

Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
por: Maes, Ken, et al.
Publicado: (2013)

Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models
por: Hu, Jinsong, et al.
Publicado: (2012)

Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
por: Fostier, Karel, et al.
Publicado: (2012)

Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells
por: De Beule, Nathan, et al.
Publicado: (2017)

Correction: Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells
por: De Beule, Nathan, et al.
Publicado: (2018)

Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies
por: De Veirman, Kim, et al.
Publicado: (2014)

Cancer Associated Fibroblasts and Tumor Growth: Focus on Multiple Myeloma
por: De Veirman, Kim, et al.
Publicado: (2014)

The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma
por: Maes, Ken, et al.
Publicado: (2014)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
por: Bieghs, Liesbeth, et al.
Publicado: (2010)

The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential
por: Bieghs, Liesbeth, et al.
Publicado: (2016)

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma
por: Maes, Ken, et al.
Publicado: (2014)

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells
por: De Veirman, Kim, et al.
Publicado: (2015)

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma
por: Emde-Rajaratnam, Martina, et al.
Publicado: (2023)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Exosomes in multiple myeloma: from bench to bedside
por: Menu, Eline, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2uq7qidtnc3q6ongm2mcmm7rf8